

Rabies Vaccine Market By Product Type (Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine, Human Rabies Immune Globulin (HRIG), Others), By Prophylaxis Type (Pre-exposure prophylaxis, Post-exposure prophylaxis), By Application (Human, Animal), By End User (Hospitals, Veterinary clinics, Others): Global Opportunity Analysis and Industry Forecast, 2025-2034

<https://marketpublishers.com/r/R12651F7BE45EN.html>

Date: December 2025

Pages: 319

Price: US\$ 2,655.00 (Single User License)

ID: R12651F7BE45EN

Abstracts

The rabies vaccine market was valued at \$1,319.90 million in 2024 and is estimated to reach \$2,041.90 million by 2034, exhibiting a CAGR of 4.5% from 2025 to 2034.

Rabies remains a significant public health concern, particularly in regions where the disease is endemic. Rabies vaccine is primarily used for post-exposure prophylaxis (PEP) after potential exposure to rabid animals and for pre-exposure prophylaxis (PrEP) for individuals at higher risk, such as veterinarians, animal handlers, and travelers. The market for rabies vaccines is supported by the increasing recognition of rabies as a preventable disease and ongoing efforts to eliminate the disease globally. The rabies vaccine market is a major segment within the global healthcare industry, focused on the development, production, and distribution of vaccines designed to prevent rabies, a fatal viral disease transmitted through the saliva of infected animals.

Rise in awareness of rabies prevention and increase in demand for post-exposure vaccination drives the growth of the rabies vaccine industry. The World Health Organization (WHO) and other global health bodies have advocated for more

widespread vaccination, leading to stronger vaccination campaigns and increased government funding, especially in endemic regions. Rapid urbanization, changes in wildlife & domestic animal populations, and an increase in international travel contribute to higher risks of rabies exposure, driving the demand for both PrEP and PEP vaccines. Furthermore, a rise in awareness of zoonotic diseases, diseases that are transmitted from animals to humans, has led to increased attention on rabies vaccination as a public health priority.

However, the high cost of rabies vaccines, particularly in low- and middle-income countries where resources for mass vaccination campaigns are limited, hinders the growth of the market. The vaccine's complex administration schedule and the need for multiple doses in post-exposure scenarios also pose challenges. In addition, there are logistical barriers related to cold chain storage and transportation, especially in rural areas where access to healthcare facilities is limited. Moreover, despite efforts to improve vaccination rates, the global prevalence of stray dogs and wildlife that carry the rabies virus remains a significant challenge.

On the other hand, initiatives by the WHO and non-governmental organizations (NGOs) to reduce human rabies deaths through mass vaccination programs and dog population management are expected to drive market growth during the forecast period. In addition, the development of improved vaccines with longer shelf lives, simpler administration methods, and more cost-effective production processes could increase accessibility. The integration of advanced technologies, such as mobile health applications and digital monitoring systems for vaccine tracking, offers opportunities for enhancing vaccination coverage in underserved areas. Lastly, expanding public-private partnerships between governments, healthcare organizations, and vaccine manufacturers offer promising prospects for market growth and rabies control. In 2020, Merck partnered with the Global Alliance for Rabies Control (GARC) and the WHO to support initiatives for rabies elimination in high-risk areas through vaccination and educational campaigns.

Segment Review

The rabies vaccine market is segmented on the basis of product type, prophylaxis type, application, end user, and region. By product type, it is segregated into chick embryo cells rabies vaccine, vero cell rabies vaccine, human diploid cell vaccine, human rabies immune globulin (HRIG) and others. By prophylaxis type, it is classified into pre-exposure prophylaxis and post-exposure prophylaxis. By application, it is categorized into humans and animals. By end user, it is divided into hospitals, veterinary clinics, and

others. By region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By product type, the chick embryo cells rabies vaccine segment held the major share of the market in 2024.

By prophylaxis type, the post-exposure prophylaxis segment dominated the global rabies vaccine market in 2024.

By application, the human segment dominated the rabies vaccine market in 2024.

By end user, the hospitals segment dominated the rabies vaccine market in 2024.

Region-wise, North America is anticipated to dominate the rabies vaccine market with the largest share during the forecast period.

Competition Analysis

The major players in the rabies vaccine market include Bharat Biotech International Limited, Zoetis, Sanofi, Boehringer Ingelheim International GmbH, Serum Institute of India Pvt. Ltd., Novartis AG, Cadila Pharmaceuticals, Merck & Co., Inc. Elanco Animal Health Incorporated., and Virbac SA. Key players operating in the market have adopted product approval, product launch, acquisition, and agreement as their key strategies to expand their rabies vaccine market share.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the rabies vaccine market analysis from 2024 to 2034 to identify the prevailing rabies vaccine market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the rabies vaccine market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue

contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global rabies vaccine market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)

5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

Free Upcoming Version on the Purchase of Five and Enterprise User License.

16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

Free data Pack on the Five and Enterprise User License. (Excel version of the report)

Free Updated report if the report is 6-12 months old or older.

24-hour priority response*

Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines

Strategic Recommendations

Additional company profiles with specific to client's interest

Additional country or region analysis- market size and forecast

Average Selling Price Analysis / Price Point Analysis

Brands Share Analysis

Criss-cross segment analysis- market size and forecast

Expanded list for Company Profiles

Historic market data

Import Export Analysis/Data

Key player details (including location, contact details, supplier/vendor network etc. in excel format)

List of customers/consumers/raw material suppliers- value chain analysis

Market share analysis of players at global/region/country level

Product Consumption Analysis

SWOT Analysis

Volume Market Size and Forecast

Key Market Segments By Product Type

Chick Embryo Cells Rabies Vaccine

Vero Cell Rabies Vaccine

Human Diploid Cell Vaccine

Human Rabies Immune Globulin (HRIG)

Others

By Prophylaxis Type

Pre-exposure prophylaxis

Post-exposure prophylaxis

By Application

Animal

Human

By End User

Hospitals

Veterinary clinics

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia-Pacific

China

Japan

India

South Korea

Australia

Rest of Asia-Pacific

LAMEA

Brazil

South Africa

Saudi Arabia

Rest of LAMEA

Key Market Players

Merck & Co., Inc.

Zoetis Inc.

Bharat Biotech International Limited

Novartis AG

Virbac SA

Boehringer Ingelheim International GmbH

Sanofi

Serum Institute of India Pvt. Ltd.

Cadila Pharmaceuticals Ltd.

Elanco Animal Health Incorporated

Contents

CHAPTER 1: INTRODUCTION

- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
 - 1.4.1. Primary research
 - 1.4.2. Secondary research
 - 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

- 3.1. Market definition and scope
- 3.2. Key findings
 - 3.2.1. Top impacting factors
 - 3.2.2. Top investment pockets
- 3.3. Porter's five forces analysis
 - 3.3.1. Moderate bargaining power of suppliers
 - 3.3.2. Moderate threat of new entrants
 - 3.3.3. Low threat of substitutes
 - 3.3.4. High intensity of rivalry
 - 3.3.5. Moderate bargaining power of buyers
- 3.4. Market dynamics
 - 3.4.1. Drivers
 - 3.4.1.1. Rise in prevalence of rabies
 - 3.4.1.2. Increase in initiative taken by the government
 - 3.4.2. Restraints
 - 3.4.2.1. Lack of awareness among people regarding rabies
 - 3.4.2.2. High cost of vaccine
 - 3.4.3. Opportunities
 - 3.4.3.1. Rise in the number of adoptions of key strategies by market players
 - 3.4.3.2. Development of low-cost and thermostable vaccines

CHAPTER 4: RABIES VACCINE MARKET, BY PRODUCT TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Chick Embryo Cells Rabies Vaccine

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Vero Cell Rabies Vaccine

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Human Diploid Cell Vaccine

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

4.5. Human Rabies Immune Globulin (HRIG)

4.5.1. Key market trends, growth factors and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market share analysis by country

4.6. Others

4.6.1. Key market trends, growth factors and opportunities

4.6.2. Market size and forecast, by region

4.6.3. Market share analysis by country

CHAPTER 5: RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Pre-exposure prophylaxis

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Post-exposure prophylaxis

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

CHAPTER 6: RABIES VACCINE MARKET, BY APPLICATION

6.1. Overview

6.1.1. Market size and forecast

6.2. Human

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Animal

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

CHAPTER 7: RABIES VACCINE MARKET, BY END USER

7.1. Overview

7.1.1. Market size and forecast

7.2. Hospitals

7.2.1. Key market trends, growth factors and opportunities

7.2.2. Market size and forecast, by region

7.2.3. Market share analysis by country

7.3. Veterinary clinics

7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by region

7.3.3. Market share analysis by country

7.4. Others

7.4.1. Key market trends, growth factors and opportunities

7.4.2. Market size and forecast, by region

7.4.3. Market share analysis by country

CHAPTER 8: RABIES VACCINE MARKET, BY REGION

8.1. Overview

8.1.1. Market size and forecast By Region

8.2. North America

8.2.1. Key market trends, growth factors and opportunities

8.2.2. Market size and forecast, by Product Type

8.2.3. Market size and forecast, by Prophylaxis Type

8.2.4. Market size and forecast, by Application

8.2.5. Market size and forecast, by End User

8.2.6. Market size and forecast, by country

8.2.6.1. U.S.

8.2.6.1.1. Market size and forecast, by Product Type

8.2.6.1.2. Market size and forecast, by Prophylaxis Type

8.2.6.1.3. Market size and forecast, by Application

8.2.6.1.4. Market size and forecast, by End User

8.2.6.2. Canada

8.2.6.2.1. Market size and forecast, by Product Type

8.2.6.2.2. Market size and forecast, by Prophylaxis Type

8.2.6.2.3. Market size and forecast, by Application

8.2.6.2.4. Market size and forecast, by End User

8.2.6.3. Mexico

8.2.6.3.1. Market size and forecast, by Product Type

8.2.6.3.2. Market size and forecast, by Prophylaxis Type

8.2.6.3.3. Market size and forecast, by Application

8.2.6.3.4. Market size and forecast, by End User

8.3. Europe

8.3.1. Key market trends, growth factors and opportunities

8.3.2. Market size and forecast, by Product Type

8.3.3. Market size and forecast, by Prophylaxis Type

8.3.4. Market size and forecast, by Application

8.3.5. Market size and forecast, by End User

8.3.6. Market size and forecast, by country

8.3.6.1. Germany

8.3.6.1.1. Market size and forecast, by Product Type

8.3.6.1.2. Market size and forecast, by Prophylaxis Type

8.3.6.1.3. Market size and forecast, by Application

8.3.6.1.4. Market size and forecast, by End User

8.3.6.2. France

8.3.6.2.1. Market size and forecast, by Product Type

8.3.6.2.2. Market size and forecast, by Prophylaxis Type

8.3.6.2.3. Market size and forecast, by Application

8.3.6.2.4. Market size and forecast, by End User

8.3.6.3. UK

8.3.6.3.1. Market size and forecast, by Product Type

8.3.6.3.2. Market size and forecast, by Prophylaxis Type

8.3.6.3.3. Market size and forecast, by Application

8.3.6.3.4. Market size and forecast, by End User

8.3.6.4. Italy

- 8.3.6.4.1. Market size and forecast, by Product Type
- 8.3.6.4.2. Market size and forecast, by Prophylaxis Type
- 8.3.6.4.3. Market size and forecast, by Application
- 8.3.6.4.4. Market size and forecast, by End User
- 8.3.6.5. Spain
 - 8.3.6.5.1. Market size and forecast, by Product Type
 - 8.3.6.5.2. Market size and forecast, by Prophylaxis Type
 - 8.3.6.5.3. Market size and forecast, by Application
 - 8.3.6.5.4. Market size and forecast, by End User
- 8.3.6.6. Rest of Europe
 - 8.3.6.6.1. Market size and forecast, by Product Type
 - 8.3.6.6.2. Market size and forecast, by Prophylaxis Type
 - 8.3.6.6.3. Market size and forecast, by Application
 - 8.3.6.6.4. Market size and forecast, by End User
- 8.4. Asia-Pacific
 - 8.4.1. Key market trends, growth factors and opportunities
 - 8.4.2. Market size and forecast, by Product Type
 - 8.4.3. Market size and forecast, by Prophylaxis Type
 - 8.4.4. Market size and forecast, by Application
 - 8.4.5. Market size and forecast, by End User
 - 8.4.6. Market size and forecast, by country
 - 8.4.6.1. China
 - 8.4.6.1.1. Market size and forecast, by Product Type
 - 8.4.6.1.2. Market size and forecast, by Prophylaxis Type
 - 8.4.6.1.3. Market size and forecast, by Application
 - 8.4.6.1.4. Market size and forecast, by End User
 - 8.4.6.2. Japan
 - 8.4.6.2.1. Market size and forecast, by Product Type
 - 8.4.6.2.2. Market size and forecast, by Prophylaxis Type
 - 8.4.6.2.3. Market size and forecast, by Application
 - 8.4.6.2.4. Market size and forecast, by End User
 - 8.4.6.3. India
 - 8.4.6.3.1. Market size and forecast, by Product Type
 - 8.4.6.3.2. Market size and forecast, by Prophylaxis Type
 - 8.4.6.3.3. Market size and forecast, by Application
 - 8.4.6.3.4. Market size and forecast, by End User
 - 8.4.6.4. South Korea
 - 8.4.6.4.1. Market size and forecast, by Product Type
 - 8.4.6.4.2. Market size and forecast, by Prophylaxis Type

8.4.6.4.3. Market size and forecast, by Application

8.4.6.4.4. Market size and forecast, by End User

8.4.6.5. Australia

8.4.6.5.1. Market size and forecast, by Product Type

8.4.6.5.2. Market size and forecast, by Prophylaxis Type

8.4.6.5.3. Market size and forecast, by Application

8.4.6.5.4. Market size and forecast, by End User

8.4.6.6. Rest of Asia-Pacific

8.4.6.6.1. Market size and forecast, by Product Type

8.4.6.6.2. Market size and forecast, by Prophylaxis Type

8.4.6.6.3. Market size and forecast, by Application

8.4.6.6.4. Market size and forecast, by End User

8.5. LAMEA

8.5.1. Key market trends, growth factors and opportunities

8.5.2. Market size and forecast, by Product Type

8.5.3. Market size and forecast, by Prophylaxis Type

8.5.4. Market size and forecast, by Application

8.5.5. Market size and forecast, by End User

8.5.6. Market size and forecast, by country

8.5.6.1. Brazil

8.5.6.1.1. Market size and forecast, by Product Type

8.5.6.1.2. Market size and forecast, by Prophylaxis Type

8.5.6.1.3. Market size and forecast, by Application

8.5.6.1.4. Market size and forecast, by End User

8.5.6.2. South Africa

8.5.6.2.1. Market size and forecast, by Product Type

8.5.6.2.2. Market size and forecast, by Prophylaxis Type

8.5.6.2.3. Market size and forecast, by Application

8.5.6.2.4. Market size and forecast, by End User

8.5.6.3. Saudi Arabia

8.5.6.3.1. Market size and forecast, by Product Type

8.5.6.3.2. Market size and forecast, by Prophylaxis Type

8.5.6.3.3. Market size and forecast, by Application

8.5.6.3.4. Market size and forecast, by End User

8.5.6.4. Rest of LAMEA

8.5.6.4.1. Market size and forecast, by Product Type

8.5.6.4.2. Market size and forecast, by Prophylaxis Type

8.5.6.4.3. Market size and forecast, by Application

8.5.6.4.4. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

- 9.1. Introduction
- 9.2. Top winning strategies
- 9.3. Product mapping of top 10 player
- 9.4. Competitive dashboard
- 9.5. Competitive heatmap
- 9.6. Top player positioning, 2024

CHAPTER 10: COMPANY PROFILES

- 10.1. Serum Institute of India Pvt. Ltd.
 - 10.1.1. Company overview
 - 10.1.2. Key executives
 - 10.1.3. Company snapshot
 - 10.1.4. Operating business segments
 - 10.1.5. Product portfolio
- 10.2. Sanofi
 - 10.2.1. Company overview
 - 10.2.2. Key executives
 - 10.2.3. Company snapshot
 - 10.2.4. Operating business segments
 - 10.2.5. Product portfolio
 - 10.2.6. Business performance
 - 10.2.7. Key strategic moves and developments
- 10.3. Boehringer Ingelheim International GmbH
 - 10.3.1. Company overview
 - 10.3.2. Key executives
 - 10.3.3. Company snapshot
 - 10.3.4. Operating business segments
 - 10.3.5. Product portfolio
 - 10.3.6. Business performance
 - 10.3.7. Key strategic moves and developments
- 10.4. Elanco Animal Health Incorporated
 - 10.4.1. Company overview
 - 10.4.2. Key executives
 - 10.4.3. Company snapshot
 - 10.4.4. Operating business segments

- 10.4.5. Product portfolio
- 10.4.6. Business performance
- 10.5. Virbac SA
 - 10.5.1. Company overview
 - 10.5.2. Key executives
 - 10.5.3. Company snapshot
 - 10.5.4. Operating business segments
 - 10.5.5. Product portfolio
 - 10.5.6. Business performance
- 10.6. Novartis AG
 - 10.6.1. Company overview
 - 10.6.2. Key executives
 - 10.6.3. Company snapshot
 - 10.6.4. Operating business segments
 - 10.6.5. Product portfolio
 - 10.6.6. Business performance
- 10.7. Cadila Pharmaceuticals Ltd.
 - 10.7.1. Company overview
 - 10.7.2. Key executives
 - 10.7.3. Company snapshot
 - 10.7.4. Operating business segments
 - 10.7.5. Product portfolio
- 10.8. Bharat Biotech International Limited
 - 10.8.1. Company overview
 - 10.8.2. Key executives
 - 10.8.3. Company snapshot
 - 10.8.4. Operating business segments
 - 10.8.5. Product portfolio
- 10.9. Zoetis Inc.
 - 10.9.1. Company overview
 - 10.9.2. Key executives
 - 10.9.3. Company snapshot
 - 10.9.4. Operating business segments
 - 10.9.5. Product portfolio
 - 10.9.6. Business performance
- 10.10. Merck & Co., Inc.
 - 10.10.1. Company overview
 - 10.10.2. Key executives
 - 10.10.3. Company snapshot

- 10.10.4. Operating business segments
- 10.10.5. Product portfolio
- 10.10.6. Business performance
- 10.10.7. Key strategic moves and developments

List Of Tables

LIST OF TABLES

TABLE 01. GLOBAL RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034 (\$MILLION)

TABLE 02. RABIES VACCINE MARKET FOR CHICK EMBRYO CELLS RABIES VACCINE, BY REGION, 2024-2034 (\$MILLION)

TABLE 03. RABIES VACCINE MARKET FOR VERO CELL RABIES VACCINE, BY REGION, 2024-2034 (\$MILLION)

TABLE 04. RABIES VACCINE MARKET FOR HUMAN DIPLOID CELL VACCINE, BY REGION, 2024-2034 (\$MILLION)

TABLE 05. RABIES VACCINE MARKET FOR HUMAN RABIES IMMUNE GLOBULIN (HRIG), BY REGION, 2024-2034 (\$MILLION)

TABLE 06. RABIES VACCINE MARKET FOR OTHERS, BY REGION, 2024-2034 (\$MILLION)

TABLE 07. GLOBAL RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034 (\$MILLION)

TABLE 08. RABIES VACCINE MARKET FOR PRE-EXPOSURE PROPHYLAXIS, BY REGION, 2024-2034 (\$MILLION)

TABLE 09. RABIES VACCINE MARKET FOR POST-EXPOSURE PROPHYLAXIS, BY REGION, 2024-2034 (\$MILLION)

TABLE 10. GLOBAL RABIES VACCINE MARKET, BY APPLICATION, 2024-2034 (\$MILLION)

TABLE 11. RABIES VACCINE MARKET FOR HUMAN, BY REGION, 2024-2034 (\$MILLION)

TABLE 12. RABIES VACCINE MARKET FOR ANIMAL, BY REGION, 2024-2034 (\$MILLION)

TABLE 13. GLOBAL RABIES VACCINE MARKET, BY END USER, 2024-2034 (\$MILLION)

TABLE 14. RABIES VACCINE MARKET FOR HOSPITALS, BY REGION, 2024-2034 (\$MILLION)

TABLE 15. RABIES VACCINE MARKET FOR VETERINARY CLINICS, BY REGION, 2024-2034 (\$MILLION)

TABLE 16. RABIES VACCINE MARKET FOR OTHERS, BY REGION, 2024-2034 (\$MILLION)

TABLE 17. RABIES VACCINE MARKET, BY REGION, 2024-2034 (\$MILLION)

TABLE 18. NORTH AMERICA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034 (\$MILLION)

TABLE 19. NORTH AMERICA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034 (\$MILLION)

TABLE 20. NORTH AMERICA RABIES VACCINE MARKET, BY APPLICATION, 2024-2034 (\$MILLION)

TABLE 21. NORTH AMERICA RABIES VACCINE MARKET, BY END USER, 2024-2034 (\$MILLION)

TABLE 22. NORTH AMERICA RABIES VACCINE MARKET, BY COUNTRY, 2024-2034 (\$MILLION)

TABLE 23. U.S. RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034 (\$MILLION)

TABLE 24. U.S. RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034 (\$MILLION)

TABLE 25. U.S. RABIES VACCINE MARKET, BY APPLICATION, 2024-2034 (\$MILLION)

TABLE 26. U.S. RABIES VACCINE MARKET, BY END USER, 2024-2034 (\$MILLION)

TABLE 27. CANADA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034 (\$MILLION)

TABLE 28. CANADA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034 (\$MILLION)

TABLE 29. CANADA RABIES VACCINE MARKET, BY APPLICATION, 2024-2034 (\$MILLION)

TABLE 30. CANADA RABIES VACCINE MARKET, BY END USER, 2024-2034 (\$MILLION)

TABLE 31. MEXICO RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034 (\$MILLION)

TABLE 32. MEXICO RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034 (\$MILLION)

TABLE 33. MEXICO RABIES VACCINE MARKET, BY APPLICATION, 2024-2034 (\$MILLION)

TABLE 34. MEXICO RABIES VACCINE MARKET, BY END USER, 2024-2034 (\$MILLION)

TABLE 35. EUROPE RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034 (\$MILLION)

TABLE 36. EUROPE RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034 (\$MILLION)

TABLE 37. EUROPE RABIES VACCINE MARKET, BY APPLICATION, 2024-2034 (\$MILLION)

TABLE 38. EUROPE RABIES VACCINE MARKET, BY END USER, 2024-2034 (\$MILLION)

TABLE 39. EUROPE RABIES VACCINE MARKET, BY COUNTRY, 2024-2034
(\$MILLION)

TABLE 40. GERMANY RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034
(\$MILLION)

TABLE 41. GERMANY RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE,
2024-2034 (\$MILLION)

TABLE 42. GERMANY RABIES VACCINE MARKET, BY APPLICATION, 2024-2034
(\$MILLION)

TABLE 43. GERMANY RABIES VACCINE MARKET, BY END USER, 2024-2034
(\$MILLION)

TABLE 44. FRANCE RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034
(\$MILLION)

TABLE 45. FRANCE RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE,
2024-2034 (\$MILLION)

TABLE 46. FRANCE RABIES VACCINE MARKET, BY APPLICATION, 2024-2034
(\$MILLION)

TABLE 47. FRANCE RABIES VACCINE MARKET, BY END USER, 2024-2034
(\$MILLION)

TABLE 48. UK RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034
(\$MILLION)

TABLE 49. UK RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034
(\$MILLION)

TABLE 50. UK RABIES VACCINE MARKET, BY APPLICATION, 2024-2034
(\$MILLION)

TABLE 51. UK RABIES VACCINE MARKET, BY END USER, 2024-2034 (\$MILLION)

TABLE 52. ITALY RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034
(\$MILLION)

TABLE 53. ITALY RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034
(\$MILLION)

TABLE 54. ITALY RABIES VACCINE MARKET, BY APPLICATION, 2024-2034
(\$MILLION)

TABLE 55. ITALY RABIES VACCINE MARKET, BY END USER, 2024-2034
(\$MILLION)

TABLE 56. SPAIN RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034
(\$MILLION)

TABLE 57. SPAIN RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034
(\$MILLION)

TABLE 58. SPAIN RABIES VACCINE MARKET, BY APPLICATION, 2024-2034
(\$MILLION)

TABLE 59. SPAIN RABIES VACCINE MARKET, BY END USER, 2024-2034
(\$MILLION)

TABLE 60. REST OF EUROPE RABIES VACCINE MARKET, BY PRODUCT TYPE,
2024-2034 (\$MILLION)

TABLE 61. REST OF EUROPE RABIES VACCINE MARKET, BY PROPHYLAXIS
TYPE, 2024-2034 (\$MILLION)

TABLE 62. REST OF EUROPE RABIES VACCINE MARKET, BY APPLICATION,
2024-2034 (\$MILLION)

TABLE 63. REST OF EUROPE RABIES VACCINE MARKET, BY END USER,
2024-2034 (\$MILLION)

TABLE 64. ASIA-PACIFIC RABIES VACCINE MARKET, BY PRODUCT TYPE,
2024-2034 (\$MILLION)

TABLE 65. ASIA-PACIFIC RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE,
2024-2034 (\$MILLION)

TABLE 66. ASIA-PACIFIC RABIES VACCINE MARKET, BY APPLICATION, 2024-2034
(\$MILLION)

TABLE 67. ASIA-PACIFIC RABIES VACCINE MARKET, BY END USER, 2024-2034
(\$MILLION)

TABLE 68. ASIA-PACIFIC RABIES VACCINE MARKET, BY COUNTRY, 2024-2034
(\$MILLION)

TABLE 69. CHINA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034
(\$MILLION)

TABLE 70. CHINA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034
(\$MILLION)

TABLE 71. CHINA RABIES VACCINE MARKET, BY APPLICATION, 2024-2034
(\$MILLION)

TABLE 72. CHINA RABIES VACCINE MARKET, BY END USER, 2024-2034
(\$MILLION)

TABLE 73. JAPAN RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034
(\$MILLION)

TABLE 74. JAPAN RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034
(\$MILLION)

TABLE 75. JAPAN RABIES VACCINE MARKET, BY APPLICATION, 2024-2034
(\$MILLION)

TABLE 76. JAPAN RABIES VACCINE MARKET, BY END USER, 2024-2034
(\$MILLION)

TABLE 77. INDIA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034
(\$MILLION)

TABLE 78. INDIA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034

(\$MILLION)

TABLE 79. INDIA RABIES VACCINE MARKET, BY APPLICATION, 2024-2034

(\$MILLION)

TABLE 80. INDIA RABIES VACCINE MARKET, BY END USER, 2024-2034

(\$MILLION)

TABLE 81. SOUTH KOREA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034 (\$MILLION)

TABLE 82. SOUTH KOREA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034 (\$MILLION)

TABLE 83. SOUTH KOREA RABIES VACCINE MARKET, BY APPLICATION, 2024-2034 (\$MILLION)

TABLE 84. SOUTH KOREA RABIES VACCINE MARKET, BY END USER, 2024-2034 (\$MILLION)

TABLE 85. AUSTRALIA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034 (\$MILLION)

TABLE 86. AUSTRALIA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034 (\$MILLION)

TABLE 87. AUSTRALIA RABIES VACCINE MARKET, BY APPLICATION, 2024-2034 (\$MILLION)

TABLE 88. AUSTRALIA RABIES VACCINE MARKET, BY END USER, 2024-2034 (\$MILLION)

TABLE 89. REST OF ASIA-PACIFIC RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034 (\$MILLION)

TABLE 90. REST OF ASIA-PACIFIC RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034 (\$MILLION)

TABLE 91. REST OF ASIA-PACIFIC RABIES VACCINE MARKET, BY APPLICATION, 2024-2034 (\$MILLION)

TABLE 92. REST OF ASIA-PACIFIC RABIES VACCINE MARKET, BY END USER, 2024-2034 (\$MILLION)

TABLE 93. LAMEA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034 (\$MILLION)

TABLE 94. LAMEA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034 (\$MILLION)

TABLE 95. LAMEA RABIES VACCINE MARKET, BY APPLICATION, 2024-2034 (\$MILLION)

TABLE 96. LAMEA RABIES VACCINE MARKET, BY END USER, 2024-2034 (\$MILLION)

TABLE 97. LAMEA RABIES VACCINE MARKET, BY COUNTRY, 2024-2034 (\$MILLION)

TABLE 98. BRAZIL RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034 (\$MILLION)

TABLE 99. BRAZIL RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034 (\$MILLION)

TABLE 100. BRAZIL RABIES VACCINE MARKET, BY APPLICATION, 2024-2034 (\$MILLION)

TABLE 101. BRAZIL RABIES VACCINE MARKET, BY END USER, 2024-2034 (\$MILLION)

TABLE 102. SOUTH AFRICA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034 (\$MILLION)

TABLE 103. SOUTH AFRICA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034 (\$MILLION)

TABLE 104. SOUTH AFRICA RABIES VACCINE MARKET, BY APPLICATION, 2024-2034 (\$MILLION)

TABLE 105. SOUTH AFRICA RABIES VACCINE MARKET, BY END USER, 2024-2034 (\$MILLION)

TABLE 106. SAUDI ARABIA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034 (\$MILLION)

TABLE 107. SAUDI ARABIA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034 (\$MILLION)

TABLE 108. SAUDI ARABIA RABIES VACCINE MARKET, BY APPLICATION, 2024-2034 (\$MILLION)

TABLE 109. SAUDI ARABIA RABIES VACCINE MARKET, BY END USER, 2024-2034 (\$MILLION)

TABLE 110. REST OF LAMEA RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024-2034 (\$MILLION)

TABLE 111. REST OF LAMEA RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024-2034 (\$MILLION)

TABLE 112. REST OF LAMEA RABIES VACCINE MARKET, BY APPLICATION, 2024-2034 (\$MILLION)

TABLE 113. REST OF LAMEA RABIES VACCINE MARKET, BY END USER, 2024-2034 (\$MILLION)

TABLE 114. SERUM INSTITUTE OF INDIA PVT. LTD.: KEY EXECUTIVES

TABLE 115. SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT

TABLE 116. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT SEGMENTS

TABLE 117. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO

TABLE 118. SANOFI: KEY EXECUTIVES

TABLE 119. SANOFI: COMPANY SNAPSHOT

TABLE 120. SANOFI: PRODUCT SEGMENTS

TABLE 121. SANOFI: PRODUCT PORTFOLIO

TABLE 122. SANOFI: KEY STRATEGIES

TABLE 123. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES

TABLE 124. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT

TABLE 125. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS

TABLE 126. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO

TABLE 127. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY STRATEGIES

TABLE 128. ELANCO ANIMAL HEALTH INCORPORATED: KEY EXECUTIVES

TABLE 129. ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT

TABLE 130. ELANCO ANIMAL HEALTH INCORPORATED: PRODUCT SEGMENTS

TABLE 131. ELANCO ANIMAL HEALTH INCORPORATED: PRODUCT PORTFOLIO

TABLE 132. VIRBAC SA: KEY EXECUTIVES

TABLE 133. VIRBAC SA: COMPANY SNAPSHOT

TABLE 134. VIRBAC SA: PRODUCT SEGMENTS

TABLE 135. VIRBAC SA: PRODUCT PORTFOLIO

TABLE 136. NOVARTIS AG: KEY EXECUTIVES

TABLE 137. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 138. NOVARTIS AG: PRODUCT SEGMENTS

TABLE 139. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 140. CADILA PHARMACEUTICALS LTD.: KEY EXECUTIVES

TABLE 141. CADILA PHARMACEUTICALS LTD.: COMPANY SNAPSHOT

TABLE 142. CADILA PHARMACEUTICALS LTD.: PRODUCT SEGMENTS

TABLE 143. CADILA PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO

TABLE 144. BHARAT BIOTECH INTERNATIONAL LIMITED: KEY EXECUTIVES

TABLE 145. BHARAT BIOTECH INTERNATIONAL LIMITED: COMPANY SNAPSHOT

TABLE 146. BHARAT BIOTECH INTERNATIONAL LIMITED: PRODUCT SEGMENTS

TABLE 147. BHARAT BIOTECH INTERNATIONAL LIMITED: PRODUCT PORTFOLIO

TABLE 148. ZOETIS INC.: KEY EXECUTIVES

TABLE 149. ZOETIS INC.: COMPANY SNAPSHOT

TABLE 150. ZOETIS INC.: PRODUCT SEGMENTS

TABLE 151. ZOETIS INC.: PRODUCT PORTFOLIO

TABLE 152. MERCK & CO., INC.: KEY EXECUTIVES

TABLE 153. MERCK & CO., INC.: COMPANY SNAPSHOT

TABLE 154. MERCK & CO., INC.: PRODUCT SEGMENTS

TABLE 155. MERCK & CO., INC.: PRODUCT PORTFOLIO

TABLE 156. MERCK & CO., INC.: KEY STRATEGIES

List Of Figures

LIST OF FIGURES

- FIGURE 01. RABIES VACCINE MARKET, 2024-2034
- FIGURE 02. SEGMENTATION OF RABIES VACCINE MARKET, 2024-2034
- FIGURE 03. TOP IMPACTING FACTORS IN RABIES VACCINE MARKET (2023 TO 2034)
- FIGURE 04. TOP INVESTMENT POCKETS IN RABIES VACCINE MARKET (2025-2034)
- FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 07. LOW THREAT OF SUBSTITUTES
- FIGURE 08. HIGH INTENSITY OF RIVALRY
- FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 10. GLOBAL RABIES VACCINE MARKET: DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11. RABIES VACCINE MARKET, BY PRODUCT TYPE, 2024 AND 2034(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR CHICK EMBRYO CELLS RABIES VACCINE, BY COUNTRY 2024 AND 2034(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR VERO CELL RABIES VACCINE, BY COUNTRY 2024 AND 2034(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR HUMAN DIPLOID CELL VACCINE, BY COUNTRY 2024 AND 2034(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR HUMAN RABIES IMMUNE GLOBULIN (HRIG), BY COUNTRY 2024 AND 2034(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR OTHERS, BY COUNTRY 2024 AND 2034(%)
- FIGURE 17. RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE, 2024 AND 2034(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR PRE-EXPOSURE PROPHYLAXIS, BY COUNTRY 2024 AND 2034(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR POST-EXPOSURE PROPHYLAXIS, BY COUNTRY 2024 AND 2034(%)
- FIGURE 20. RABIES VACCINE MARKET, BY APPLICATION, 2024 AND 2034(%)
- FIGURE 21. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR HUMAN, BY COUNTRY 2024 AND 2034(%)
- FIGURE 22. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET

FOR ANIMAL, BY COUNTRY 2024 AND 2034(%)

FIGURE 23. RABIES VACCINE MARKET, BY END USER, 2024 AND 2034(%)

FIGURE 24. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR HOSPITALS, BY COUNTRY 2024 AND 2034(%)

FIGURE 25. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR VETERINARY CLINICS, BY COUNTRY 2024 AND 2034(%)

FIGURE 26. COMPARATIVE SHARE ANALYSIS OF RABIES VACCINE MARKET FOR OTHERS, BY COUNTRY 2024 AND 2034(%)

FIGURE 27. RABIES VACCINE MARKET BY REGION, 2024 AND 2034(%)

FIGURE 28. U.S. RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 29. CANADA RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 30. MEXICO RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 31. GERMANY RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 32. FRANCE RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 33. UK RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 34. ITALY RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 35. SPAIN RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 36. REST OF EUROPE RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 37. CHINA RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 38. JAPAN RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 39. INDIA RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 40. SOUTH KOREA RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 41. AUSTRALIA RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 42. REST OF ASIA-PACIFIC RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 43. BRAZIL RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 44. SOUTH AFRICA RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 45. SAUDI ARABIA RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 46. REST OF LAMEA RABIES VACCINE MARKET, 2024-2034 (\$MILLION)

FIGURE 47. TOP WINNING STRATEGIES, BY YEAR (2024-2025)

FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT (2024-2025)

FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY (2024-2025)

FIGURE 50. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 51. COMPETITIVE DASHBOARD

FIGURE 52. COMPETITIVE HEATMAP: RABIES VACCINE MARKET

FIGURE 53. TOP PLAYER POSITIONING, 2024

FIGURE 54. SANOFI: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 55. SANOFI: REVENUE SHARE BY SEGMENT, 2024 (%)

FIGURE 56. SANOFI: REVENUE SHARE BY REGION, 2024 (%)

FIGURE 57. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2022-2024 (\$MILLION)

FIGURE 58. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY SEGMENT, 2024 (%)

FIGURE 59. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY REGION, 2024 (%)

FIGURE 60. ELANCO ANIMAL HEALTH INCORPORATED: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 61. ELANCO ANIMAL HEALTH INCORPORATED: RESEARCH & DEVELOPMENT EXPENDITURE, 2022-2024 (\$MILLION)

FIGURE 62. VIRBAC SA: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 63. NOVARTIS AG: NET SALES, 2022-2024 (\$MILLION)

FIGURE 64. NOVARTIS AG: REVENUE SHARE BY REGION, 2024 (%)

FIGURE 65. ZOETIS INC.: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 66. ZOETIS INC.: REVENUE SHARE BY REGION, 2024 (%)

FIGURE 67. MERCK & CO., INC.: NET SALES, 2022-2024 (\$MILLION)

I would like to order

Product name: Rabies Vaccine Market By Product Type (Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine, Human Rabies Immune Globulin (HRIG), Others), By Prophylaxis Type (Pre-exposure prophylaxis, Post-exposure prophylaxis), By Application (Human, Animal), By End User (Hospitals, Veterinary clinics, Others): Global Opportunity Analysis and Industry Forecast, 2025-2034

Product link: <https://marketpublishers.com/r/R12651F7BE45EN.html>

Price: US\$ 2,655.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R12651F7BE45EN.html>